Abstract:Engineering peptide-based targeting agents with residues for site-specific and stable complexation of radionuclides is a highly desirable strategy for producing diagnostic and therapeutic agents for cancer and other diseases. In this report, a model N-S-N-py ligand (3) and a cysteine-derived alpha-melanocyte stimulating hormone (alpha-MSH) peptide (6) were used as novel demonstrations of a widely applicable chelation strategy for incorporation of the [M-I(CO)(3)](+) (M = Re, Tc-99m) core into peptide-based molecules for radiopharmaceutical applications. The structural details of the core ligand metal complexes as model systems were demonstrated by full chemical characterization of fac-[Re-I(CO)(3)(N,S,N-py-3)](+) (4) and comparative high-performance liquid chromatography (HPLC) analysis between 4 and [Tc-99m(I)(CO)(3)(N,S,N-py-3)](+) (4a). The alpha-MSH analogue bearing the N-S-N-py chelate on a modified cysteine residue (6) was generated and complexed with [M-I(CO)(3)](+) to confirm the chelation strategy's utility when applied in a peptide-based targeting agent. Characterization of the Re-I(CO)(3)-6 peptide conjugate (7) confirmed the efficient incorporation of the metal center, and the Tc-99m(I)(CO)(3)-6 analogue (7a) was explored as a potential single photon emission computed tomography (SPECT) compound for imaging the melanocortin 1 receptor (MC1R) in melanoma. Peptide 7a showed excellent radiolabeling yields and in vitro stability during amino acid challenge and serum stability assays. In vitro B16F10 melanoma cell uptake of 7a reached a modest value of 2.3 +/- 0.08% of applied activity at 2 h at 37 degrees C, while this uptake was significantly reduced by coincubation with a nonlabeled a-MSH analogue, NAPamide (3.2 mu M) (P < 0.05). In vivo SPECT/X-ray computed tomography (SPECT/CT) imaging and biodistribution of 7a were evaluated in a B16F10 melanoma xenografted mouse model SPECT/CT imaging clearly visualized the tumor at 1 h post injection (p.i.) with high tumor-to-background contrast Blocking studies with coinjected NAPamide (10 mg per kg of mouse body weight) confirmed the in vivo specificity of 7a for MC1R-positive tumors. Biodistribution results with 7a yielded a moderate tumor uptake of 1.20 +/- 0.09 percentage of the injected radioactive dose per gram of tissue (%ID/g) at 1 h p.i. Relatively high uptake of 7a was also seen in the kidneys and liver at 1 h p.i. (6.55 +/- 0.36% ID/g and 444 +/- 0.17% ID/g, respectively), although reduced kidney uptake was seen at 4 h p.i. (3.20 +/- 0.48% ID/g). These results demonstrate the utility of the novel [M-I(CO)(3)](+) chelation strategy when applied in a targeting peptide.

Trigonal scaffolds for multivalent targeting of melanocortin receptors

Synthesis and evaluation of bivalent ligands for binding to the human melanocortin-4 receptor

Novel Cocrystal Structures of Peptide Antagonists Bound to the Human Melanocortin Receptor 4 Unveil Unexplored Grounds for Structure-Based Drug Design

Structural insights into ligand recognition and subtype selectivity of the human melanocortin-3 and melanocortin-5 receptors

The Parallel Structure–Activity Relationship Screening of Three Compounds Identifies the Common Agonist Pharmacophore of Pyrrolidine Bis-Cyclic Guanidine Melanocortin-3 Receptor (MC3R) Small-Molecule Ligands

Ψ and χ Angle Constrains at the C-Terminus Trp Position of the Melanotropin Tetrapeptide Ac-His-d-Phe-Arg-Trp-NH2 Lead to Potent and Selective Agonists at hMC1R and hMC4R

Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs)

Structural insights into ligand recognition and activation of the melanocortin-4 receptor

Synthesis and Biological Activity of Novel Peptide Mimetics As Melanocortin Receptor Agonists

Molecular Determinants of Ligand Binding to the Human Melanocortin-4 Receptor

Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Structural mechanism of calcium-mediated hormone recognition and Gβ interaction by the human melanocortin-1 receptor

Modeling and Docking of the Three-Dimensional Structure of the Human Melanocortin 4 Receptor

Design and Synthesis of a Bivalent Ligand to Explore the Putative Heterodimerization of the Mu Opioid Receptor and the Chemokine Receptor CCR5.

Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging

Effects of the Arg-Pro and Gly-Gly-Nle Moieties on Melanocortin-1 Receptor Binding Affinities of Α-Msh Peptides.

Hqsar and Topomer Comfa for Predicting Melanocortin-4 Receptor Binding Affinities of Trans-4-(4-Chlorophenyl) Pyrrolidine-3-Carboxamides

Analogs of alpha-melanocyte stimulating hormone with high agonist potency and selectivity at human melanocortin receptor 1b: the role of Trp(9) in molecular recognition

Chimeras of the agouti-related protein: insights into agonist and antagonist selectivity of melanocortin receptors

Identification of antagonists for melanocortin MC3, MC4 and MC5 receptors

Novel, cysteine-modified chelation strategy for the incorporation of [MI(CO)3]+ (M = Re, 99mTc) in an α-MSH peptide